Hepatitis B: Future curative strategies

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 528-534

  Bertoletti, Antonio ^a,b,c   Rivino, Laura ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chronic hepatitis B; Toll like receptor agonist; Vaccine therapy

Indexed keywords

ANTIVIRUS AGENT; CIRCULAR DNA; HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 8 AGONIST; UNCLASSIFIED DRUG; VIRUS PROTEIN; ALPHA INTERFERON; ALPHA2B INTERFERON; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DNA DEGRADATION; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL; MONOCYTE; NATURAL KILLER T CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS ENTRY; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; LIVER; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84927796555     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000110     Document Type: Review

References (65)

1. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. ELife 2012; 1:e00049-e00049.
2. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146:1070-1083.
3. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014; 147:48-64.
4. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61:1754-1764.
5. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68-76.
6. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81:4215-4225.
7. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
8. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191:1269-1280.
9. Webster GJM, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78:5707-5719.
10. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178:1541-1554.
11. Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194:1755-1766.
12. Sitia G, Isogawa M, Iannacone M, et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004; 113:1158-1167.
13. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8:275-284.
14. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343:1221-1228.
15. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16:295-308.
16. Chen J, Zhang W, Lin J, et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther 2013; 22:303-311.
17. Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87:6599-6603.
18. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013; 21:973-985.
19. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26:335-341.
20. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94:907.
21. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010; 52:616-619.
22. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long term effective treatment with nucleos(t)ide analogues. Gastroenterology 2012; 143:963.e9-973.e9.
23. Schurich A, Khanna P, Lopes AR, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53:1494-1503.
24. Michel ML, Pol S, Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19:2395-2399.
25. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009; 3:561-569.
26. Pol S, Nalpas B, Driss F, et al. Multicenter study group: efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34:917-921.
27. Vandepapeliè re P, Lau GKK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25:8585-8597.
28. Mancini-Bourgine M, Fontaine HLN, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40:874-882.
29. Heathcote J, McHutchison J, Lee S, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30:531-536.
30. Godon O, Fontaine H, Kahi S, et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2013; 22:675-684.
31. Fontaine H, Kahi S, Chazallon C, et al., ANRS HB02 study group. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial-ANRS HB02 VAC-ADN. Gut 2014. [Epub ahead of print] This study reported the clinical and virological efficacy of therapeutic vaccination in CHB patients.
32. Kakimi K, Isogawa M, Chung J, et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 2002; 76:8609-8620.
33. Depla E, Van der Aa A, Livingston BD, et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2007; 82:435-450.
34. Buchmann P, Dembek C, Kuklick L, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31:1197-1203.
35. King TH, Kemmler CB, Guo Z, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One 2014; 9:e101904.
36. Kosinska AD, Johrden L, Zhang E, et al. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol 2012; 86:9297-9310.
37. Kosinska AD, Zhang E, Johrden L, et al. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 2013; 9:e1003391.
38. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014; 10:e1003856.
39. Xu DZ, Wang XY, Shen XL, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59:450-456.
40. Kool M, SoulliéT, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869-882.
41. Huang LR, Wohlleber D, Reisinger F, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013; 14:574-583.
42. Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8+ t cells from PD-1-mediated exhaustion. PLoS Pathog 2013; 9:e1003490.
43. Lan P, Zhang C, Han Q, et al. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 2013; 58:73-85.
44. Lv S, Wang J, Dou S, et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 2014; 59:385-394.
45. Gehring AJ, Haniffa M, Kennedy PT, et al. Mobilizing monocytes to crosspresent circulating viral antigen in chronic infection. J Clin Invest 2013; 123:3766-3776.
46. Krebs K, Böttinger N, Huang LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013; 145:456-465.
47. Gehring AJ, Xue S-A, Ho ZZ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011; 55:103-110.
48. Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25:1497-1501.
49. Loggi E, Bihl F, Chisholm JV, et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 2009; 50:625-630.
50. Koh S, Shimasaki N, Suwanarusk R, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013; 2:e114.
51. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74:4165-4173.
52. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74:2255-2264.
53. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81:7351-7362.
54. Watashi K, Liang G, Iwamoto M, et al. Interleukin-1 and tumor necrosis factor- A trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem 2013; 288:31715-31727.
55. Fisicaro P, Valdatta C, Boni C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58:974-982.
56. Bertoletti A, Gehring AJ. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 2013; 9:e1003784.
57. Zoulim F, Luangsay S, Durantel D. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B. Gastroenterology 2013; 144:1342-1344.
58. Ji C, Sastry KSR, Tiefenthaler G, et al. Targeted delivery of interferon- A to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 2012; 56:2027-2038.
59. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis b virus in chronically infected chimpanzees. Gastroenterology 2013; 144:1508.e10-1517.e10.
60. Tang XZ, Jo J, Tan AT, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 2013; 190:3142-3152.
61. Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis b virus replication in the livers of transgenic mice. J Virol 2002; 76:10702-10707.
62. Schurich A, Pallett LJ, Lubowiecki M, et al. The third signal cytokine IL-12 rescues the antiviral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9:e1003208.
63. Jo J, Tan AT, Ussher JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 2014; 10:e1004210.
64. Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012; 109:E2165-E2172.
65. Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012; 143:637-645.